ArticleScientific reports2022

A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction.

Kevin Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.